Patients with lower limb vascular disease are at an increased risk of thrombotic events. Tissue plasminogen activator (t-PA) and plasminogen activator inhibitor 1 (PAI-1) are important components of the fibrinolytic system, responsible for clot lysis. This study aimed to establish whether peroneal nerve stimulation (PNS) could promote fibrinolysis within a cohort of vascular patients. Ethical approval was obtained for this prospective case-controlled study. Patients were randomly assigned to active stimulation or control groups. Arterial flow measurements and venous blood samples were taken bilaterally at baseline and following 45 min of PNS. ELISA analysis for plasma t-PA and PAI-1 was performed utilizing commercially available kits. Statistical analysis evaluated the changes in t-PA and PAI-1 levels from baseline for the active (device active), passive (contralateral limb) and control limbs (inactive device applied). Seventy-seven participants were recruited: 30 claudicants (25 active and five controls), 25 patients postoperative infra-inguinal bypass grafts (19 active and six controls) and 22 patients with varicose veins (17 active and five controls). t-PA levels reduced significantly in all groups; however, intergroup analysis demonstrated no statistically significant difference when comparing the active, passive and control limbs (P U 0.079). PAI-1 levels decreased by 16.2% (34.0 ng/ml, SD 52.2) in the active limbs but only 3.6% (11.4 ng/ml, SD 47.4) and 2.6% (2.7 ng/ml, SD 21.3) in the passive and control limbs, respectively (intergroup analysis P < 0.001). No relationship between changes in flow and plasma of t-PA and PAI-1 were demonstrated. Peroneal nerve stimulation may augment fibrinolysis by decreasing plasma levels of PAI-1 levels in patients with lower limb arterial and venous disease. Blood Coagul Fibrinolysis 27:275-280
Introduction
Vessel occlusion secondary to thrombosis can result in permanent damage to tissues, and as such, the endogenous fibrinolytic system works to protect against such event [1] . Studies have demonstrated that patients with vascular disease often have prothrombotic tendencies [2] . Endothelial dysfunction caused by the risk factors for peripheral arterial occlusive disease result in increased platelet activation and aggregation. It has also been reported that the presence of varicose veins increases the risk of deep vein thrombosis formation [3] .
Tissue plasminogen activator (t-PA) is slowly released by the endothelium following vascular injury promoting fibrinolysis through the conversion of plasminogen to plasmin [4] . As a result, it has therapeutic uses in clinical medicine to treat thrombosis and emboli. Its activity is regulated by fibrin levels. t-PA and its antigen's levels increase in the presence of inflammation and antigen levels appears to be correlated to the levels of inflammatory markers such a C reactive protein and leucocyte count [5, 6] .
The action of t-PA is usually inhibited by plasminogen activator inhibitors (PAI) 1 and 2; however, activation of the endothelium results in an imbalance and the creation of a pro-coaguable state. Deficiency of PAI-1 leads to bleeding tendencies, whilst overexpression leads to increased tendencies towards thrombosis whilst increased levels have been shown to be a risk factor for the development of coronary artery disease, myocardial infarctions, deep vein thrombosis [7] .
Hypercoagulation or impaired fibrinolysis results in increased fibrin deposition within vessels and development of thrombosis. It can therefore be seen that t-PA and PAI-1 play an important role in thrombotic vascular disease [8, 9] . This has led to the development of treatments such as alteplase, which are utilized in the treatment of acute thrombotic events [10] . It has also been suggested that reduction in cardiovascular mortality seen with statins may also be due in part to their activity on the fibrinolytic system [11] . However, all medications have incumbent side effects and as such alternative therapies that may provide the beneficial effects without the risks are being sought.
This study aimed to establish whether peroneal nerve stimulation has an impact upon plasma levels of t-PA and PAI-1 in patients with peripheral vascular disease. of this study. The participants were identified from the vascular outpatient department and those attending for vascular duplex assessment at Hull Royal Infirmary. Three patient groups were recruited: claudicants; patients post infra-inguinal bypass grafts; and patients with varicose veins. Potential participants were assessed for eligibility and if suitable were issued with a patient information sheet. Written consent was obtained for all participants. To enable determination as whether there was any systemic alteration in plasma concentrations, the final five or six participants recruited from each patient group were control patients, that is the stimulation device was applied but not activated.
Materials and methods

Participants
Delivery of stimulation
Peroneal nerve stimulation was delivered using the geko transcutaneous neuromuscular electrical stimulation device (CE 558928; British Standards Institute notified body 0086, Firstkind Ltd). It delivers a pulsed electrical current at 27 mA at a repetition rate of 1 Hz. There are seven pulse width settings ranging from 70 to 560 ms allowing adjustments for patient comfort. It is applied, as per manufacturer's instructions, to the posterolateral aspect of the knee to stimulate the peroneal nerve in the popliteal fossa. The stimulation level was increased until a muscle twitch was visible whilst ensuring tolerability.
Study procedures
The study procedures were carried out in a designated temperature controlled clinical room. Participants were required to abstain from stimulants prior to their examination and wore light garments with their legs exposed. Only after ensuring adherence to the protocol, the study commenced inclusion and exclusion criteria.
The individuals were positioned semi-recumbent on a padded examination couch, with their knees slightly flexed. Following a 30-min acclimatization period, 20 ml of systemic blood was drawn and duplex assessment of superficial femoral arterial volume flow performed.
All participants for active stimulation had the stimulation intensity of the geko device increased until visible muscle stimulation was evident (concentric isotonic contractions) or until patient tolerance was reached as per Cramp et al. [12] . Patients who were not for active stimulation had the device applied but not turned on.
After 45 min of stimulation, 15-20 ml of blood was drawn from the femoral veins bilaterally using a 21-gauge needle, under ultrasound visualization and repeat measurements of arterial volume flow were made.
Following sampling, the blood was immediately decanted into bottles and inverted a minimum of five times to ensure complete mixing prior to centrifugation at 1500g for 15 min (after 30 min standing). The plasma was then decanted into 1 ml aliquots and labelled for freezing at À808C. Prior to assay, the frozen sample was brought to room temperature slowly and mixed gently.
ELISA analysis
The ELISA analysis was undertaken at the University of Hull in the Centre for Biomedical Research. Samples were analysed blinded. Commercially available functional assays were utilized (eBioscience Platinum ELISA kits; Affymetrix, eBioscience. San Diego, USA). The plate reader absorbance values were recorded for each well, standard and sample, subtracting the absorbance measured in the blank wells. A standard curve was created by plotting the mean absorbance of each standard concentration against the human PAI-1 and t-PA concentration. A best fit curve was then drawn through the points on the graph. The concentrations of circulating PAI-1 and t-PA were then determined by utilizing the mean absorbance value for each sample.
All samples were processed in duplicate, and if the results were within 5%, the mean was utilized. If the variability between sample duplicates was greater than 5%, the samples were rerun.
Statistical analysis
All data were transcribed into a secure dedicated database (Microsoft Excel, 2013; Microsoft, Reading, UK). All analyses were performed utilizing SPSS (Chicago, Illinois, USA). No assumptions were made prior to analysis regarding the direction of relationships and no imputation of missing data was attempted.
For the purpose of statistical analysis, the results were divided into three groups:
(1) Active; limb on which the device was active;
(2) Passive; contralateral limb to the active limb;
(3) Control; limb on which the device was applied but not turned on.
Intragroup analysis of changes from baseline was carried out using the paired t-test and intergroup analysis of differences in change from baseline was assessed utilizing the analysis of variance (ANOVA) test with posthoc Bonferonni analysis.
Results
Seventy-seven participants were recruited into the study: 30 claudicants (25 active and five controls), 25 patients postoperative infra-inguinal bypass grafts (19 active and six controls) and 22 patients with varicose veins (17 active and five controls).
Volume flow
The mean change in arterial volume flow from baseline in the active limbs was 31.5%, passive 1.1% and control -2.8%. The difference between the active and passive (P < 0.001) and active and control (P < 0.001) were statistically significant, although there was no difference between the passive and control limbs (P ¼ 1.000).
Tissue plasminogen activator
The mean baseline t-PA level was significantly higher in the infra-inguinal bypass group 5260.3 pg/ml (SD 2070.1) than the claudicants 3714.3 pg/ml (SD 1368.1) (P < 0.001) and varicose vein group 3903.0 pg/ml (SD 1034.9) (P < 0.001), although there was no significant difference between the claudicants and varicose vein groups (P ¼ 1.000).
The mean baseline t-PA level, for all participants, in the active and passive groups was 4260.0 pg/ml (SD 1649.5), whilst the mean baseline t-PA level in the control group was 4291.4 pg/ml (SD 1723.0). The difference in mean t-PA at baseline was not statistically significant (unpaired ttest P ¼ 1.000).
The baseline levels of t-PA were compared in the presence or absence of risk factors for vascular disease and concomitant medication use ( Table 1 ). The baseline level of t-PA was statistically significantly lower in patients who were taking warfarin or clopidogrel and significantly higher in individuals with cardiovascular disease.
The mean change in t-PA in the active group was À302.4 pg/ml (SD 428.2) equating to a percentage change of -7.7%. Intragroup analysis demonstrated that the change in t-PA from baseline in the active group was statistically significant (paired t-test P < 0.001). The mean change in t-PA in the passive group was À271.3 pg/ml (SD 467.8) equating to a percentage change of -5.5% (P < 0.001). The mean change in t-PA in the control group was -287.2 pg/ml (SD 383.1) equating to a percentage change of -6.85% (P < 0.001). Intergroup analysis was performed utilizing the ANOVA test, which demonstrated that the differences in the changes seen in the three groups were not statistically significant (P ¼ 0.079) ( Fig. 1 ).
Linear regression did not reveal a relationship between the change in arterial volume flow and the change in t-PA level (Fig. 2) .
Plasminogen activator inhibitor-1 levels
There was no statistically significant difference in baseline PAI-1 when comparing the bypass patients 207.0 ng/ ml (SD 71.9), claudicants 185.5 ng/ml (SD 68.3) or patients with varicose veins 194.9 (SD 106.2) ng/ml (P ¼ 0.393). A comparison of baseline PAI-1 levels in the presence and absence of risk factors and concomitant medications was performed ( Table 2) . Plasma concentration of t-PA (pg/ml) 8 ,000
10,000
Boxplot demonstrating change in plasma tissue plasminogen activator (t-PA) concentration. Inter-group analysis demonstrated that the difference between change in PAI-1 between the groups was statistically significant (P ¼ 0.002). Post hoc Bonferonni testing demonstrated that the difference between the active and control limbs was statistically significant (P ¼ 0.006), active and passive (0.019); however, the difference between the control and passive limbs was not statistically significant (P ¼ 1.000) ( Fig. 3) .
No relationship was demonstrated between the change in PAI-1 level and the change in blood volume flow (Fig. 4 ).
Discussion
Effect of disease states on fibrinolytic markers In this study, higher baseline levels of tissue plasminogen activator were present in patients with hypertension and cardiovascular disease including atrial fibrillation. This finding corresponds to the existing literature [5, 13] . t-PA levels have been demonstrated to be higher in patients with nonvalvular atrial fibrillation than age-matched controls [14] . The activity levels were found to decrease following treatment with warfarin or heparin. Higher t-PA and PAI-1 levels have also been shown to be associated with development of acute myocardial infarction and remain higher following the events than age-matched controls [15] . Further studies have also demonstrated that elevated t-PA and PAI-1 correlated with serum levels of triglycerides and BMI and that the t-PA/ PAI-1 complex is a risk factor for recurrent myocardial infarctions [16] . For t-PA, the increased risk of cardiovascular events was an independently established risk factor for cardiovascular events [17] . Elevated levels of t-PA antigen have also been reported to be independently associated with an increased risk of ischaemic stroke in nondiabetic women [18] and to be associated with an increased risk of developing diabetes mellitus [19] .
This study failed to demonstrate an association between higher PAI-1 levels and the presence of cardiovascular disease or risk factors for vascular disease, which contradicts the findings of some existing literature [15, 16, 20] .
278 Blood Coagulation and Fibrinolysis 2016, Vol 27 No 3 However, a systematic review by Gorog et al. [1] determined that fibrinolytic markers have a very limited role in predicting vascular disease or risk stratification due to the poor quality and low power of the existing studies. Baseline plasma plasminogen activator inhibitor levels were determined in this study to be significantly higher in patients with respiratory disease. This finding reflects that reported previously as fibrosis of the lungs results from the accumulation of extracellular matrix in both the interstitial tissues and the basement membranes as a result of imbalance in its synthesis and degradation [21] . Degradation of extracellular matrix is a function of the plasminogen activator system [22] .
Effect of concomitant medications on fibrinolytic markers
This study has demonstrated that warfarin therapy is associated with statistically significantly lower levels of PAI-1, whilst clopidogrel and warfarin were associated with higher levels of t-PA.
The impact of warfarin treatment on plasma levels of t-PA and PAI-1 has been investigated in several distinct patient populations with contradictory results. A study investigating the effects of warfarin and aspirin on thrombogenesis in patients with chronic atrial fibrillation demonstrated that following 8 weeks of treatment with warfarin alone, PAI-1 levels were not altered; however, combination therapy of aspirin and warfarin resulted in an increase in PAI-1 [23] . However, treatment of patients postcoronary artery bypass graft with 1 mg of warfarin has not been shown to affect t-PA or PAI-1 levels [24] . Similarly, a study of chronic ambulatory peritoneal dialysis patients has shown that PAI-levels are not affected by warfarin therapy within this patient cohort [25] .
Clopidogrel has been shown in studies to have a nonplatelet-related effect on levels of plasminogen activator inhibitor levels, resulting in lower levels [26, 27] . This does not reflect the findings of this study as whilst lower, the difference in PAI-1 level did not reach statistical significance. This may be due to insufficient patient numbers, as only 13 patients within the cohort were treated with clopidogrel.
In this study, aspirin usage did not impact upon baseline levels of t-PA. Studies have previously shown that aspirin inhibits the normal physiological increase in t-PA activity following venous occlusion [28] . However, Levin et al. [29] demonstrated that aspirin affects t-PA activity by inhibiting the release of t-PA antigen.
Effect of nerve stimulation on fibrinolytic markers
Electrical stimulation of the peroneal nerve has no effect on t-PA levels when compared with the control participants. It is known that t-PA and u-PA are present in sensory neurons. Electrical cardiac stimulation has been shown to result in increased t-PA release into the circulation and activity with increases in heart rate, blood pressure and coronary blood flow [30, 31] . Similarly, Jawad et al. [32] reported a decrease in t-PA antigen with use of the geko device.
This study has demonstrated a statistically significant reduction in plasma PAI-1 in vascular patients following a period of peroneal nerve stimulation. However, the results are local and not systemic as seen by comparing the results of the active and passive samples.
These findings reflect the existing literature. A study in 1979 demonstrated that electrical nerve stimulation resulted in release of tissue thromboplastin and stimulators of fibrinolysis [33] . Another animal study examined vagal nerve electrical stimulation demonstrating an increase in plasminogen activator inhibitor 1 [34] . In these studies, however, it is believed that the increase in fibrinolytic factors is in response to increased blood coagulability and is as such a protective mechanism. More recently, Katz et al. [35] examined the effect of electrical stimulation on patients with spinal cord injuries and determined that fibrinolytic activity was increased.
Increasing fibrinolytic activity by reducing levels of plasminogen activator inhibitor 1 could have many beneficial long-term effects through the prevention of thrombosis. Increased PAI-1 levels have been shown to be implicated in the ageing-associated thrombosis and cardiovascular ageing [36] . As such, the ability to reduce circulating levels may slow disease progression in the elderly. Reducing plasma levels of PAI-1 have also been shown in experiments to slow progression of chronic kidney disease and may even result in a degree of disease resolution, which has led to attempts to develop drugs and therapies, which could target its activity [37] . It has also been shown that high levels of PAI-1 may be responsible for the development of microvascular complications associated with Type II diabetes mellitus [38] . It can therefore be seen that peroneal nerve stimulation would be a useful treatment adjunct or prophylaxis within the vascular disease population, many of whom have multiple risk factors for thrombotic disease.
Conclusion
Peroneal nerve stimulation decreases plasminogen activator inhibitor 1 levels in patients with lower limb arterial and venous disease. As such, it may have a role in augmenting fibrinolysis within this patient cohort and therefore reduce thrombotic events.
